Alltrna Announces Series B Raise Of $109 Million To Advance Trna Medicines For Stop Codon Disease
08/09/23, 10:06 AM
Location
Industry
therapeutics
artificial intelligence
biotechnology
health care
Round Type
series b
Investors
Flagship Pioneering
Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease, today announced that it has raised $109 million in a Series B financing to advance the company's platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease. The financing round included the company's founder, Flagship Pioneering, and a number of top-tier investors.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Alltrna unlocks tRNA biology to treat disease. The company’s platform incorporates AI/ML tools to develop and deliver diverse programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single tRNA medicine to readthrough premature stop codons and unify treatment across a wide range of diseases with the same underlying genetic mutations. Alltrna was founded in 2018 by Flagship Pioneering.